TMSB4X: A Potential Drug Target and Biomarker (G7114)

Target Name: TMSB4X

NCBI ID: G7114

TMSB4X

TMSB4X: A Potential Drug Target and Biomarker

Tissue factor X (TFX) is a transmembrane protein that is expressed in various tissues and cells, including heart, liver, and kidneys. TFX is involved in the regulation of hemostasis, which is the process by which the body forms and maintains blood clots to prevent excessive bleeding. Mutations in the TFX gene have been linked to various hemostatic disorders, including hemophilia and von Willebrand disease.

In recent years, there has been increasing interest in TFX as a potential drug target for the treatment of hemophilia and other hemostatic disorders. One reason for this is the recent approval of several drugs for the treatment of hemophilia B, a genetic disorder that causes excessive bleeding. These drugs work by inhibiting the activity of FIX, which is a protein that is involved in the regulation of blood clotting.

Another reason for the interest in TFX is its potential as a biomarker for the diagnosis and monitoring of hemostatic disorders. The ability to measure the expression of TFX provides a sensitive and specific method for evaluating the severity of hemostatic disorders and determining the effectiveness of potential therapeutic interventions.

TFX is a 21-kDa protein that is expressed in various tissues and cells. It consists of an N-terminus that is involved in the regulation of the actin cytoskeleton (8), a C-terminus that is involved in the regulation of integrins (9), and a middle region that contains the catalytic domain.

The function of TFX is to regulate the activity of integrins, which are a type of protein that is involved in cell adhesion and migration. Integrins are composed of an alpha chain and an beta chain that are held together by a single alpha-beta interface. The alpha chain contains several subunits that are involved in the regulation of integrin interactions with various cell surface molecules.

TFX is involved in the regulation of integrin interactions with the protein Fc portion of platelet. Fc is a portion of the platelet that is responsible for the binding of clotting factors to the damaged blood vessel. TFX regulates the activity of integrins Fc伪2 and Fc尾3, which are involved in the regulation of integrin interactions with Fc.

Mutations in the TFX gene have been linked to various hemostatic disorders. For example, mutations in the TFX gene have been linked to the development of hemophilia B, a genetic disorder that causes excessive bleeding. In hemophilia B, the activity of FIX is defective, which results in the inability to form blood clots and an increased risk of bleeding.

In addition to its role in the regulation of hemostasis, TFX has also been shown to be involved in the regulation of inflammation. TFX has been shown to be involved in the regulation of the production of pro-inflammatory cytokines, such as TNF-alpha.

TFX has also been shown to be involved in the regulation of cellular signaling pathways. For example, TFX has been shown to be involved in the regulation of the PI3K/Akt signaling pathway. This pathway is involved in the regulation of cellular signaling pathways, including the regulation of cell growth, differentiation, and survival.

In conclusion, TFSB4X is a protein that is involved in the regulation of hemostasis and inflammation. Its activity is regulated by various interactions with other proteins, including Fc, integrins, and intracellular signaling pathways. The potential of TFX as a drug target for the treatment of hemophilia and other hemostatic disorders is based on its role in the regulation of

Protein Name: Thymosin Beta 4 X-linked

Functions: Plays an important role in the organization of the cytoskeleton (PubMed:1999398, PubMed:10848969). Binds to and sequesters actin monomers (G actin) and therefore inhibits actin polymerization (PubMed:1999398, PubMed:10848969)

The "TMSB4X Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMSB4X comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets